A carregar...
Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells
BACKGROUND: Platinum plus paclitaxel is a first-line chemotherapy for ovarian cancer. Platinum resistance is a hot topic for many scholars, but drug resistance caused by paclitaxel is also a topic of concern. Currently, scholars believe that inhibition of MAPK signaling pathway may be an effective w...
Na minha lista:
| Publicado no: | Med Sci Monit |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scientific Literature, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7466840/ https://ncbi.nlm.nih.gov/pubmed/32829374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.922612 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|